Mechanisms for the neutral or lower MetS risk with CHB have been proposed by an increase in adiponectin, which has anti-inflammation, anti-oxidation, anti-fibrosis, and immunomodulation effects [33]. This evidence concerns the gene ADIPOQ and metabolic syndrome.